NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

IO Biotech secures €57.5 million loan facility from EIB to support cancer vaccine development, extending cash runway to 2026. IO Biotech has secured a loan facility of up to €57.5 million from the ...

Io Biotech (NASDAQ:IOBT), a clinical-stage oncology company specializing in cancer vaccines, released its second quarter results on August 14, 2025. The most important update was the outcome of the ...

Aug 11 (Reuters) - IO Biotech (IOBT.O), opens new tab said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's progression in a late-stage study, but ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment ...

Our motto is investing in innovative healthcare solutions. Our fund is two-thirds biotech, and for that, we’re looking for the J curve. We want to focus on the value inflections that we can unlock in ...

Cash and cash equivalents as of September 30, 2024 were $80.2 million, compared to $143.2 million at December 31, 2023. During the three months ended September 30, 2024, the company used cash, cash ...

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, ...

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data ...